Abstract 504P
Background
Evidence on the role of induction systemic therapy is limited for stage III NSCLC patients who cannot undergo upfront local therapy due to locally extensive disease or baseline poor lung function.
Methods
We analyzed 81 patients with Stage III Non-Oncogene driven NSCLC deemed ineligible for upfront local therapy by Thoracic MDT between September 2015 and January 2023, retrospectively. Of those, 44 patients received a combination of induction chemotherapy (IC) with low-dose immunotherapy (Nivolumab-42; Pembrolizumab-2) as concurrent or maintenance or both (NACT+I/O group) and 37 patients received only IC (NACT-only group) followed by assessment for local therapy. IC was platinum doublet in both groups, median number of cycles was four. Immunotherapy was given as induction only (n=26), maintenance only (n=7) or both (n=11) based on physician preference and practical feasibility. For Nivolumab, 24 patients received >0.6mg/kg q2weekly whereas 18 received <0.6mg/kg q2weekly dose. Outcomes analyzed were proportion of patients undergoing local therapy, median PFS, OS and toxicity data.
Results
Baseline characteristics are outlined in given table. 70% of patients underwent subsequent local therapy in both NACT+I/O and NACT-only groups. Median PFS was 27.5 months in NACT+I/O Group vs 13.7 months in NACT-only group (p=0.01). Median OS was 39.3 months in NACT+I/O Group vs 25.2 months in NACT-only group (p=0.21). Grade ≥3 toxicities observed in NACT + I/O vs NACT groups were hematological (7 vs 2), diarrhea (1 vs 1) and fatigue (1 vs 1). Table: 504P
Baseline characteristics
Parameter | NACT+I/O group (n=44) | NACT-Only group (n=37) |
Median Age (IQR) | 59 (49-65) | 61 (54-64) |
MaleFemale | 368 | 343 |
AdenocarcinomaSquamousMixed | 19205 | 11233 |
StageIIIAIIIBIIIC | 72413 | 11206 |
Local Therapy RadiotherapySurgeryNil | 26513 | 22413 |
Last follow-up No diseasePartial responseStable diseaseProgressive diseaseDead | 1241378 | 30101311 |
Conclusions
Induction systemic therapy resulted in the conversion of 70% stage III NSCLC to local therapy in our experience. The use of low-dose immunotherapy along with chemotherapy was safe and yielded a significant PFS benefit and numerically higher OS benefit. This may prove to be a cost-effective option for stage III NSCLC patients ineligible for upfront local therapy, especially in LMIC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract